Episode 1: Precision Automation Meets Biology

Central question: How can automation help scientists move faster without losing sight of the biology?

This opening episode would introduce precision automation as the connective tissue across the Molecular Devices portfolio. Rather than defining automation simply as higher throughput, we would explore how purpose-built tools help biologists reduce repetitive work, control variability, improve consistency, and focus more of their time on scientific decisions.

Potential discussion points:

• What “precision automation” means for a working biologist
• Why automation should adapt to the science — not force the science into a rigid process
• Where manual variability enters cell-based research
• The balance between speed, consistency, flexibility, and scientific control
• How purpose-built instruments, software, and expertise work together
• Why researchers may need different solutions at different points in their journey

Speaker: Matt Stoltz

Moderator: Uduak Thomas

Hosted on Acast. See acast.com/privacy for more information.

Artificial intelligence is advancing quickly into laboratory operations, which is why thinking about the quality and integrity of the supporting data early on is important. In regulated environments, that means understanding where the data came from, how it changes, and how AI-generated insights or recommendations can be traced, reviewed, trusted, and ultimately defended.

In this GEN podcast, LabVantage’s Gary Stimson digs into what it takes to build a data foundation for trustworthy AI. The discussion covers concepts like data lineage, traceability, explainability and governance, and the importance of audit-ready laboratory operations. It also looks at the role of intended use, ongoing monitoring, and human review in deploying AI responsibly.

Hosted on Acast. See acast.com/privacy for more information.

Small molecules continue to play a major part in pharmaceutical development, but increasing molecular complexity, accelerated timelines, and evolving manufacturing and regulatory requirements are creating new challenges for the industry.

In this GEN Podcast – part 2 in a 3-part series -- a trio of experts from SK Pharmteco discuss how CDMOs are helping biopharma companies navigate critical areas including scale-up, technology transfer, advanced manufacturing, automation, sustainability, the emergence of AI, and supply chain reliability. The discussion explores practical strategies for improving development efficiency while supporting quality, scalability, and long-term commercial success.

Guest Speakers

Steve Barr, PhD -- Head of Small Molecule Business Unit and VP Global Alliances, SK Pharmteco.

Darryl Ratty -- Executive Director of Global ESG (Environmental, Social and Governance), SK Pharmteco.

Bill Dubay -- VP, Global Research and Development, SK Pharmteco.

Moderator:

Kevin Davies, PhD, Editorial Director, GEN

Hosted on Acast. See acast.com/privacy for more information.